Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 543

1.

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS.

Ann Intern Med. 2001 Jul 17;135(2):73-87. Erratum in: Ann Intern Med 2002 Aug 20;137(4):299.

PMID:
11453706
2.

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.

Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group..

Ann Intern Med. 2003 Aug 19;139(4):244-52.

PMID:
12965979
4.
5.
6.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.

Am J Kidney Dis. 2000 Jun;35(6):1155-65.

PMID:
10845831
7.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

8.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382
9.

Renal protection and antihypertensive drugs: current status.

Salvetti A, Mattei P, Sudano I.

Drugs. 1999 May;57(5):665-93. Review.

PMID:
10353294
11.

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease..

Kidney Int. 2001 Sep;60(3):1131-40.

12.

The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.

Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS.

Nephrol Dial Transplant. 2003 Oct;18(10):2047-53.

13.

Renoprotective effects of antihypertensive drugs.

Preston RA.

Am J Hypertens. 1999 Jan;12(1 Pt 2):19S-32S. Review.

PMID:
10077416
14.

The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.

Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z; Amlodipine Versus Enalapril in Renal failure (AVER) Study Group..

Clin Ther. 2008 Mar;30(3):482-98. doi: 10.1016/j.clinthera.2008.03.006.

PMID:
18405787
15.

Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.

Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Janin G, Zucchelli P.

J Cardiovasc Pharmacol. 1999;33 Suppl 1:S16-20; discussion S41-3.

PMID:
10028949
16.

Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.

Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G.

Ann Intern Med. 1989 Sep 15;111(6):503-16. Review.

PMID:
2491421
17.

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials.

Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE.

Am J Kidney Dis. 2000 Apr;35(4):695-707.

PMID:
10739792
18.
19.
20.
Items per page

Supplemental Content

Support Center